A5045341937- Cancer Genomics and Diagnostics
- Biotechnology and Related Fields
- Cardiac Ischemia and Reperfusion
- Reconstructive Surgery and Microvascular Techniques
- Anesthesia and Neurotoxicity Research
- Cardiac Arrhythmias and Treatments
- Reservoir Engineering and Simulation Methods
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
- Genetics and Neurodevelopmental Disorders
- Microfluidic and Bio-sensing Technologies
- Cardiac, Anesthesia and Surgical Outcomes
- Reconstructive Facial Surgery Techniques
- Bone fractures and treatments
- Neuroscience and Neuropharmacology Research
- Microfluidic and Capillary Electrophoresis Applications
- Systemic Sclerosis and Related Diseases
- Organ and Tissue Transplantation Research
- Pregnancy and preeclampsia studies
- Hydraulic Fracturing and Reservoir Analysis
- Ocular Oncology and Treatments
- Epilepsy research and treatment
- Radio Frequency Integrated Circuit Design
- Protein Degradation and Inhibitors
- Cancer-related Molecular Pathways
Cornell University
2022-2025
Weill Cornell Medicine
2022-2025
University of Saskatchewan
2022-2024
Island Hospital
2024
Komfo Anokye Teaching Hospital
2024
University of Toronto
2014-2023
Shell (Netherlands)
2023
Baylor Medical Center at Garland
2023
Cairns Hospital
2023
Monash University
2018-2022
We introduce Opacus, a free, open-source PyTorch library for training deep learning models with differential privacy (hosted at opacus.ai). Opacus is designed simplicity, flexibility, and speed. It provides simple user-friendly API, enables machine practitioners to make pipeline private by adding as little two lines their code. supports wide variety of layers, including multi-head attention, convolution, LSTM, GRU (and generic RNN), embedding, right out the box means supporting other...
Abstract Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapeutic strategies. Yet, some targetable genes and pathways essential for tumor cell viability even in the absence of direct alterations. In underrepresented populations, mutational landscape determinants response existing therapies poorly characterized because limited inclusion clinical trials studies. One way reveal is with genetic screens. Most...
In pretransplantation therapy busulfan is typically given every 6 hours. We infused once daily at 130 mg/m2 for 4 days, performing pharmacokinetic analyses on plasma concentration-time data (n = 60 patients) days 1, 3, and/or 4. Mean (percent coefficient of variation) maximum concentration, volume distribution, half-life, and clearance were 3.6 microg/mL (13.8%), 22.6 L/m2 (20.2%), 2.73 hours (27.5%), 109 mL/min/m2 (26%), respectively. The mean median areas under the curve 4873 (21.8%) 4871...
SummaryHippo was first identified in a genetic screen as protein that suppressed proliferation and cell growth. Subsequently, it shown hippo acted so-called canonical cascade to suppress Yorkie, the Drosophila equivalent of Yes-activated (YAP), mechanosensitive transcriptional cofactor enhances activity TEAD family transcription factors. YAP promotes fibrosis, activation cancer-associated fibroblasts, angiogenesis cancer invasion. activates expression matricellular proteins CCN1 (cyr61) CCN2...
This paper reports the first study of stiffness/deformability changes lymphocytes in chronic lymphocytic leukemia (CLL) patients, demonstrating that at single cell level, leukemic metastasis progresses are accompanied by biophysical property alterations. A microfluidic device was utilized to electrically measure volume and transit time from healthy CLL patients. The results testing thousands cells reveal patients have higher stiffness (i.e., lower deformability), as compared samples, which...
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with BRCA1/2 mutations, but other mutations may benefit from PARPi treatment. Another mutation that is present in more cancers than to the TP53 gene. In 2D breast cancer cell lines, mutant p53 (mtp53) proteins tightly associate replicating DNA and (PARP) protein. Combination drug treatment alkylating agent temozolomide talazoparib kills mtp53 expressing grown lines. We evaluated sensitivity combination of plus lung...
<p>PDTOs breast cancer subtype analysis</p>
<p>IC50 values (µM) obtained for tested inhibitors in breast PDTO lines.</p>
<p>List of raw gRNA counts</p>
<p>List of primers and vectors used in this study.</p>
<p>List of inhibitors tested in HTDS alone or combination with gefitinib.</p>
<p>PDTO breast media composition.</p>
<p>Patient clinical information</p>
<div>Abstract<p>Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapeutic strategies. Yet, some targetable genes and pathways essential for tumor cell viability even in the absence of direct alterations. In underrepresented populations, mutational landscape determinants response existing therapies poorly characterized because limited inclusion clinical trials studies. One way reveal is with genetic...
<p>Supplementary Figures 1-7</p>